Amneal Pharmaceuticals Stock Forecast, Price & News

Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

Is Amneal Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amneal Pharmaceuticals stock.
View analyst ratings for Amneal Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Amneal Pharmaceuticals?

Wall Street analysts have given Amneal Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amneal Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Amneal Pharmaceuticals.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its earnings results on Sunday, August, 8th. The company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.07. The company had revenue of $535.10 million for the quarter, compared to analysts' expectations of $523.26 million. Amneal Pharmaceuticals had a net margin of 0.45% and a trailing twelve-month return on equity of 58.68%. The business's quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.13 EPS.
View Amneal Pharmaceuticals' earnings history.

How has Amneal Pharmaceuticals' stock price been impacted by COVID-19?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMRX shares have increased by 60.3% and is now trading at $5.21.
View which stocks have been most impacted by COVID-19.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of $0.700-$0.850 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.820. The company issued revenue guidance of $2.10 billion-$2.20 billion, compared to the consensus revenue estimate of $2.12 billion.

What price target have analysts set for AMRX?

5 equities research analysts have issued 12-month target prices for Amneal Pharmaceuticals' stock. Their forecasts range from $5.50 to $9.00. On average, they anticipate Amneal Pharmaceuticals' stock price to reach $7.40 in the next year. This suggests a possible upside of 42.0% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:

• Chintu Patel, Co-Chief Executive Officer & Director
• Chirag K. Patel, President & Co-Chief Executive Officer & Director
• Andrew S. Boyer, Executive Vice President-Commercial Operations
• Anastasios G. Konidaris, Chief Financial Officer & Senior Vice President
• Nikita Shah, Chief Human Resources Officer & Senior VP

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals CEO Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among Amneal Pharmaceuticals' employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amneal Pharmaceuticals' key competitors?

Some companies that are related to Amneal Pharmaceuticals include Allakos (ALLK), Perrigo (PRGO), I-Mab (IMAB), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), TG Therapeutics (TGTX), Arvinas (ARVN), Cerevel Therapeutics (CERE), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Hypera (HYPMY), 23andMe (ME), Arena Pharmaceuticals (ARNA) and Karuna Therapeutics (KRTX).
View all of AMRX's competitors.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.82%), BlackRock Inc. (2.36%), Neuberger Berman Group LLC (1.12%), State Street Corp (0.91%), Nuveen Asset Management LLC (0.74%) and Victory Capital Management Inc. (0.64%). Company insiders that own Amneal Pharmaceuticals stock include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco and Paul M Meister.
View institutional ownership trends for Amneal Pharmaceuticals.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Cubist Systematic Strategies LLC, Prudential Financial Inc., Parametric Portfolio Associates LLC, and Group One Trading L.P..
View insider buying and selling activity for Amneal Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Globeflex Capital L P, Vanguard Group Inc., State Street Corp, LSV Asset Management, Goldman Sachs Group Inc., and Charles Schwab Investment Management Inc.. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, and Paul M Meister.
View insider buying and selling activity for Amneal Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $5.21.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals has a market capitalization of $1.57 billion and generates $1.99 billion in revenue each year. The company earns $91.06 million in net income (profit) each year or $0.52 on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals employs 6,000 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

Where are Amneal Pharmaceuticals' headquarters?

Amneal Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at (908) 947-3120 or via email at [email protected].